Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Neovia, a Seattle-Beijing JV, Starts US Trial of Cancer Drug

publication date: Jan 26, 2017
Neovia Oncology of Seattle enrolled its first patient in a Phase I trial of NEV-80, a novel, multi-inhibitor drug aimed at increasing immunotherapy response in patients with advanced drug-resistant cancers. Neovia is a JV owned by Seattle's ANU and PUMC Pharma of Beijing. Founded in 1995, PUMC discovered NEV-80. The company works with the Peking Union Medical College (PUMC), the Chinese Ministry of Health and international partners to develop innovative drug products. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital